1Hospital Universitario de Jaén. Allergology Department, Jaén, Spain
2Hospital Santa Bárbara. Allergology Department, Puertollano, Spain
3Hospital Costa de la Luz de Huelva. Allergology Department, Huelva, Spain
4Hospital Universitario Infanta Cristina. Allergology Department, Badajoz, Spain
5Hospital Nisa. Allergology Department, Seville, Spain
6ROXALL España, R&D Department, Zamudio, Spain
History:
Published online: 27 November 2019
Accepted: 25 November 2019
Received:29 August 2019
. To evaluate the tolerability and efficacy of Olea europaea subcutaneous immunotherapy (SCIT) on patients with rhinoconjunctivitis.
. In this open clinical trial patients were assigned to an abbreviated build-up scheme. The outcomes were: number, percentage, and severity of adverse reactions. Secondary outcomes included: changes in immunoglobulin titers and changes in dose-response skin prick tests. Results. Only 8 systemic reactions were registered, which represented 7/47 (14.9%) of patients and 8/429 (1.9%) of administered doses. Regarding immunological parameters the significant increases of sIgG and sIgG4 evidenced the changes in the patient immune system. Cutaneous reactivity decreased significantly.
. Olea europaea SCIT (Allergovac® depot ROXALL Medicina España S.A.) showed a good safety and tolerability profile. Immunological changes with induction of blocking IgG and decreases in cutaneous reactivity were detected in the patients.
Olea europaea; subcutaneous immunotherapy; rhinoconjunctivitis; abbreviated schedule; depot extracts